The News

7TM Pharma appoints new Chairman of the Board

01/11/2007

Hørsholm – November 1st, 2007:
7TM Pharma A/S today announced the appointment of Peter Chambré as its new Chairman of the Board. He succeeds Paul Nicholson who passed away in August this year.

Mette Kirstine Agger, CEO of 7TM Pharma, said: "Peter is a highly experienced and successful biotech executive and we are delighted that Peter has agreed to join the company. We look forward very much to working with Peter and benefiting from his experience and expertise in the further development of 7TM Pharma.”

Peter Chambré, 51, is former Chief Executive Officer of Cambridge Antibody Technology Group plc (CAT). He led CAT from 2002 in its transition from technology focused biotechnology company to profitable biopharmaceutical company, until its acquisition by AstraZeneca plc in 2006. Previously he was Chief Operating Officer of Celera Genomics Group and Chief Executive Officer of Bespak plc. He is currently a Non-Executive Director of BTG plc and Spectris plc and advisor to 3i plc, the Private Equity Group.

Peter Chambré, Chairman of 7TM Pharma, said: “In my view, 7TM Pharma is a high quality company, which is principally focused on the important area of developing new drugs for the treatment of metabolic diseases and obesity. I have been very impressed with the company’s people and approach and I very pleased to be able to have the opportunity of working with the Board and management of 7TM Pharma during the next phase of the company’s development.”

7TM Pharma
Contact persons: Mette Kirstine Agger, CEO Direct: +45 3925 7767 E-mail: agger@7tm.com
Peter Chambré, Chairman
Tel: +45 3925 7764

About Peter Chambré
Peter Chambré is new chairman of the board in 7TM Pharma, a biotech company located in Hørsholm north of Copenhagen. Peter has a background in the British biotech industry and this summer he received “Outstanding Achievement Award”, a price from UKTI (United Kingdom Trade and Investment) for his work in the sector. Peter Chambré was CEO of the British biotech company CAT (Cambridge Antibody Technology) until its acquisition by Astra Zeneca in 2006 for GBP 702 million.

About 7TM Pharma
7TM Pharma is a biotech company focusing on discovery and development of new drugs targeting 7TM receptors. 7TM Pharma’s primary therapeutic area is metabolic diseases, including obesity, diabetes and cardiovascular diseases. According to the WHO, there are more than 400 million clinically obese people worldwide, and the number is growing rapidly. In spite of this, there are only few approved therapies for obesity with limited effect.
The basis for 7TM Pharma’s drug discovery is thorough and comprehensive knowledge about 7TM receptors and their structures, which the company uses in the design of new potential drugs. In recent years, the company has established a broad pipeline of research and development programs based on in-house drug discovery and development, and entered into several research partnerships, including with Ortho-McNeil Inc. (a subsidiary of Johnson & Johnson).
Since its inception in 2000, 7TM Pharma has raised DKK 610 million (EUR 82 million). Investors include Index Ventures, Novo A/S, Alta Partners, LD Pensions, Johnson & Johnson Development Corporation, Dansk Innovationsinvestering, Sofinnova Capital, Healthcare Private Equity Limited Partnership, Lombard Odier Darier Hentsch & Cie, SR One, Global Life Science Ventures, Baker/Tisch Investments, Credit Agricole Private Equity, GIMV and BioMedinvest AG.